Valuation: Haleon plc

Market Cap 29.82B 39.62B 35.71B 32.99B 56.42B 3,716B 57.81B 395B 158B 1,990B 149B 146B 6,333B P/E 2026 *
17.8x
P/E 2027 * 15.8x
Enterprise Value 36.96B 49.1B 44.26B 40.89B 69.93B 4,605B 71.65B 490B 195B 2,466B 184B 180B 7,849B EV / Sales 2026 *
3.27x
EV / Sales 2027 * 3.13x
Free-Float
98.31%
Yield 2026 *
2.37%
Yield 2027 * 2.59%
1 day+1.21%
1 week+0.87%
Current month+7.60%
1 month-3.13%
3 months-4.51%
6 months+2.59%
Current year-8.30%
1 week 329
Extreme 329
343.68
1 month 310.5
Extreme 310.5
433.6
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 2021-07-21
Director of Finance/CFO 58 2024-10-31
Chief Tech/Sci/R&D Officer 63 2025-07-31
Director TitleAgeSince
Director/Board Member 59 2022-05-22
Chairman 71 2025-12-31
Director/Board Member 59 2022-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/26 Buy

Director

7,670 0.0001%
9/22/26 Buy 2,139 0.0000%
9/22/26 Buy 12,209 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.21%+0.87%-9.10%+6.42% 39.62B
+0.35%+1.36%+45.38%+140.47% 1,280B
-0.13%+1.48%+44.67%+90.43% 675B
+0.37%+0.05%+31.00%+112.84% 521B
+0.88%+3.55%+39.67%+69.88% 386B
-0.59%-2.11%+61.83%+45.16% 363B
+1.51%+0.36%+28.56%+59.06% 301B
+1.01%-0.09%+3.79%+36.90% 286B
+0.62%-2.17%+38.31%+75.12% 253B
-0.67%-2.72%+38.49%+123.56% 211B
Average +0.62%-0.42%+32.26%+75.99% 432B
Weighted average by Cap. +0.82%+0.20%+39.22%+96.55%

Financials

2026 *2027 *
Net sales 11.29B 15B 13.52B 12.49B 21.36B 1,407B 21.89B 150B 59.65B 753B 56.28B 55.09B 2,397B 11.66B 15.49B 13.96B 12.9B 22.06B 1,453B 22.61B 155B 61.62B 778B 58.14B 56.9B 2,476B
Net income 1.67B 2.22B 2B 1.85B 3.16B 208B 3.24B 22.14B 8.83B 111B 8.33B 8.15B 355B 1.85B 2.46B 2.22B 2.05B 3.5B 231B 3.59B 24.56B 9.79B 124B 9.24B 9.04B 393B
Net Debt 7.14B 9.48B 8.55B 7.9B 13.51B 889B 13.84B 94.64B 37.72B 476B 35.59B 34.84B 1,516B 6.67B 8.86B 7.98B 7.38B 12.61B 831B 12.93B 88.39B 35.23B 445B 33.24B 32.53B 1,416B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
26-11-12 GBX 343.68 +1.32% 1,070,397
26-11-11 GBX 339.20 +1.25% 32,425,649
26-11-10 GBX 335.00 +1.27% 49,235,014
26-11-09 GBX 330.80 -2.39% 59,983,553
26-11-06 GBX 338.90 -0.53% 41,825,204
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.392GBP
Average target price
3.776GBP
Spread / Average Target
+11.31%